A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study

Giulia Maggioni, Matteo Bersanelli, Erica Travaglino, Ana Alfonso Piérola, Annika Kasprzak, Arnan Sangerman Montserrat, Elisabetta Sauta, Claudia Sala, Tommaso Matteuzzi, Manja Meggendorfer, Matteo Gnocchi, Lin‐Pierre Zhao, Cristina Astrid Tentori, Kathrin Nachtkamp, Daniele Dall’Olio, Ettore Mosca, Marta Ubezio, Alessia Campagna, Antonio Russo, Giulia Rivoli, Massimo Bernardi, Lorenza Borin, Maria Teresa Voso, Marta Riva, Esther Natalie Olíva, Matteo Zampini, Elena Riva, Elena Saba, Saverio D’Amico, Luca Lanino, Benedetta Tinterri, Francesca Re, Marilena Bicchieri, Laura Giordano, Giovanni Angelotti, Pierandrea Morandini, Anne Sophie Kubasch, Francesco Passamonti, Alessandro Rambaldi, Victor Savevski, Armando Santoro, Arjan A. van de Loosdrecht, Alice Brogi, Valeria Santini, Shahram Kordasti, Guillermo Sanz, Françesc Solé, Norbert Gattermann, Wolfgang Kern, Uwe Platzbecker, Lionel Adès, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Ulrich Germing, María Díez‐Campelo, Matteo Giovanni Della PortaThe Lancet Haematology 2022 · DOI

Abstract: This study was supported by the European Union (Horizon 2020 and Transcan programs), the Italian Association for Cancer Research, the Italian Ministry of Health, and the Italian Ministry of University and Research.

Introduction

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by cytopenias, ineffective hematopoiesis, and a variable risk of progression to acute myeloid leukemia (AML). For over a decade, the Revised International Prognostic Scoring System (IPSS-R) has served as the clinical gold standard for risk stratification. However, the IPSS-R treats biological sex as a confounding variable rather than a fundamental driver of disease biology.

This study, published in The Lancet Haematology, challenges this paradigm. By analyzing a massive cohort of over 13,000 patients, researchers demonstrate that sex significantly influences the genotype, phenotype, and clinical trajectory of MDS. Integrating sex-specific data into prognostic models allows for a more accurate, personalized approach to patient care.

Study Design and Methodology

The researchers conducted a multicentre, observational cohort study involving 13,284 patients across four major international registries. The study utilized a combination of retrospective and prospective data to develop and validate new prognostic systems.

Overview of study cohorts and flow, detailing the integration of retrospective and prospective data from over 13,000 participants.

The methodology employed several advanced computational techniques:

  • Genomic Profiling: Targeted sequencing was used to analyze mutations in 44 MDS-related genes.
  • Mutation Dynamics: Bradley-Terry models estimated the temporal order of mutation acquisition, while Bayesian networks inferred conditional dependencies between specific mutations.
  • Prognostic Modeling: The team developed the Sex-informed Prognostic Scoring System (PSS), which integrates sex and age with IPSS-R variables, and the Sex-informed Genomic Scoring System (GSS), which incorporates mutational data.

Genomic Sex Bias

A central finding of the study is that the molecular "starting point" of MDS differs significantly between men and women. Mutations and cytogenetic abnormalities are not distributed equally across the sexes.

Comparison of cytogenetic abnormalities between men and women, demonstrating clear sex-specific genomic profiles in MDS.

Men were found to be significantly more likely to carry mutations in genes such as ASXL1, SRSF2, and ZRSR2. Conversely, women showed an enrichment for DNMT3A and TP53 mutations, as well as a higher prevalence of del(5q) abnormalities. These genomic disparities suggest that the biological mechanisms driving disease initiation and progression are sex-dependent.

Clinical Outcomes and Survival Disparities

The study confirmed that men generally face worse outcomes, with a median overall survival significantly shorter than that of women (e.g., 81.3 months vs. 123.5 months in the EuroMDS cohort). Crucially, the researchers discovered that this survival gap is primarily driven by non-leukemic death—specifically cardiac and renal complications—rather than a higher rate of AML transformation.

Furthermore, the impact of clinical markers like hemoglobin levels was found to be sex-dependent. Anemia serves as a negative prognostic factor at higher thresholds in men (<11 g/dL) compared to women (<10 g/dL), suggesting that current "one-size-fits-all" clinical thresholds may be misleading.

Improved Prognostic Accuracy and Re-stratification

The sex-informed models demonstrated superior performance compared to the traditional IPSS-R. The Sex-informed Genomic Scoring System (GSS) achieved a Concordance Index (C-index) of 0.74–0.76, compared to 0.68 for the IPSS-R.

Most importantly, the application of these new models resulted in the re-stratification of 42–56% of patients. This indicates that approximately half of the patients studied were previously assigned to inaccurate risk categories under the IPSS-R, potentially leading to suboptimal treatment decisions.

Conclusion and Future Directions

This research marks a shift toward sex-informed precision medicine in hematology. By recognizing sex as a core biological component of MDS, clinicians can better predict outcomes and tailor interventions, particularly in early-stage disease where comorbidity management is vital.

Future efforts should focus on integrating these models into prospective clinical trials and exploring the underlying biological mechanisms—such as sex hormones or X-chromosome dynamics—that drive these observed disparities. To facilitate clinical adoption, the researchers have launched a web portal for sex-informed outcome predictions.

Summary updated

Abstract

European Union (Horizon 2020 and Transcan programs), Italian Association for Cancer Research, Italian Ministry of Health, and Italian Ministry of University and Research.
BibTeX
@inproceedings{maggioni2022sex,
  author = {Giulia Maggioni and Matteo Bersanelli and Erica Travaglino and Ana Alfonso Piérola and Annika Kasprzak and Arnan Sangerman Montserrat and Elisabetta Sauta and Claudia Sala and Tommaso Matteuzzi and Manja Meggendorfer and Matteo Gnocchi and Lin‐Pierre Zhao and Cristina Astrid Tentori and Kathrin Nachtkamp and Daniele Dall’Olio and Ettore Mosca and Marta Ubezio and Alessia Campagna and Antonio Russo and Giulia Rivoli and Massimo Bernardi and Lorenza Borin and Maria Teresa Voso and Marta Riva and Esther Natalie Olíva and Matteo Zampini and Elena Riva and Elena Saba and Saverio D’Amico and Luca Lanino and Benedetta Tinterri and Francesca Re and Marilena Bicchieri and Laura Giordano and Giovanni Angelotti and Pierandrea Morandini and Anne Sophie Kubasch and Francesco Passamonti and Alessandro Rambaldi and Victor Savevski and Armando Santoro and Arjan A. van de Loosdrecht and Alice Brogi and Valeria Santini and Shahram Kordasti and Guillermo Sanz and Françesc Solé and Norbert Gattermann and Wolfgang Kern and Uwe Platzbecker and Lionel Adès and Pierre Fenaux and Torsten Haferlach and Gastone Castellani and Ulrich Germing and María Díez‐Campelo and Matteo Giovanni Della Porta},
  title = {{A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study}},
  booktitle = {The Lancet Haematology},
  year = {2022},
  doi = {10.1016/s2352-3026(22)00323-4},
}
Figure